Donanemab: FDA experts recommend approval of Alzheimer ' s drug

被引：7
|
作者：
Dyer, Owen
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2024年 / 385卷
关键词：
D O I：
10.1136/bmj.q1327
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] NICE rejects Alzheimer's drug donanemab owing to cost and " significant health risks"
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
  • [32] Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's
    Song, Tanya
    Wang, Yunfei
    Silverglate, Bret David
    Grossberg, George T.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (06) : 411 - 417
  • [33] Alzheimer's drug approval spotlights blood tests
    Servick, Kelly
    SCIENCE, 2021, 373 (6553) : 373 - 374
  • [34] FDA provides fastest drug approval
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2012, 13 (07): : E287 - E287
  • [35] Donanemab: An innovative solution for Alzheimer's disease?
    Bin Faheem, Muhammad Shaheer
    Ishaque, Ghazal
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2024, 89 : 13 - 14
  • [36] FDA drug approval summaries: Oxaliplatin
    Ibrahim, A
    Hirschfeld, S
    Cohen, MH
    Griebel, DJ
    Williams, GA
    Pazdur, R
    ONCOLOGIST, 2004, 9 (01): : 8 - 12
  • [37] LUPUS DRUG NEARS FDA APPROVAL
    不详
    CHEMICAL & ENGINEERING NEWS, 2010, 88 (47) : 17 - 17
  • [38] THE FDA AND PRIVATIZATION - THE DRUG APPROVAL PROCESS
    RUTHERFORD, EM
    FOOD AND DRUG LAW JOURNAL, 1995, : 203 - 225
  • [39] Drug approval: Future aspects of the FDA
    Skelly, JP
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1998, 20 (06): : 527 - 537
  • [40] FDA Drug Approval and the Ethics of Desperation
    Largent, Emily A.
    Peterson, Andrew
    Lynch, Holly Fernandez
    JAMA INTERNAL MEDICINE, 2021, 181 (12) : 1555 - 1556
12345